A Phase 3 study of REM-001 in cutaneous metastatic breast cancer (CMBC) patients
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Rostaporfin (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Kintara Therapeutics; TuHURA Biosciences
Most Recent Events
- 17 Oct 2024 According to a TuHURA Biosciences media release, company announced merger with Kintara Therapeutics, Inc. and the combined company will operate under the name "TuHURA Biosciences, Inc.''
- 16 Feb 2024 New trial record
- 12 Feb 2024 According to a Kintara Therapeutics media release, the open label 15-patient study in CMBC patients is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation.